Dasatinib Accord Healthcare: Uses, Dosage & Side Effects
A potent multi-targeted tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia
Dasatinib Accord Healthcare is a generic formulation of dasatinib, a potent second-generation tyrosine kinase inhibitor (TKI) used in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib works by inhibiting BCR-ABL, the oncogenic fusion protein that drives the uncontrolled growth of leukemia cells, as well as SRC family kinases and several other kinase targets. Available as 20 mg film-coated tablets, this medication is taken orally once daily and is approximately 325 times more potent than imatinib against unmutated BCR-ABL in vitro. Dasatinib represents a critical therapeutic option for patients who are newly diagnosed with chronic phase CML or who have developed resistance or intolerance to prior TKI therapy.
Quick Facts: Dasatinib Accord Healthcare
Key Takeaways
- Dasatinib Accord Healthcare is a generic formulation of dasatinib, a second-generation BCR-ABL tyrosine kinase inhibitor that is approximately 325 times more potent than imatinib against unmutated BCR-ABL and active against most imatinib-resistant mutations (except T315I).
- It is approved for newly diagnosed adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase, as well as for patients with CML in any phase or Ph+ ALL who are resistant to or intolerant of prior TKI therapy including imatinib.
- Regular blood count monitoring is essential because dasatinib commonly causes myelosuppression (low blood counts), including severe neutropenia, thrombocytopenia, and anemia that may require dose interruption or reduction.
- Pleural effusion (fluid around the lungs) is a distinctive side effect of dasatinib, occurring in up to 35% of patients in long-term studies, requiring clinical monitoring and potentially dose adjustment, diuretics, or drainage.
- Dasatinib has significant drug interactions: strong CYP3A4 inhibitors increase its levels, strong CYP3A4 inducers decrease its levels, and acid-reducing agents (PPIs, H2 blockers, antacids) impair its absorption due to pH-dependent solubility.
What Is Dasatinib Accord Healthcare and What Is It Used For?
Dasatinib Accord Healthcare is a generic medicine containing dasatinib as its active substance. It belongs to a class of anticancer drugs known as tyrosine kinase inhibitors (TKIs). Dasatinib was originally developed under the brand name SPRYCEL by Bristol-Myers Squibb and was first approved by the U.S. Food and Drug Administration (FDA) in June 2006 and by the European Medicines Agency (EMA) in November 2006. Following patent expiry, generic formulations such as Dasatinib Accord Healthcare have been approved, providing the same active substance with demonstrated bioequivalence to the originator product.
The development of dasatinib represents a landmark achievement in the targeted therapy of hematologic malignancies. To understand how dasatinib works, it is essential to understand the molecular basis of the diseases it treats. Chronic myeloid leukemia (CML) and certain cases of acute lymphoblastic leukemia (ALL) are driven by the Philadelphia chromosome, an abnormal chromosome created by a reciprocal translocation between chromosomes 9 and 22 [t(9;22)(q34;q11)]. This translocation fuses the BCR gene on chromosome 22 with the ABL1 gene on chromosome 9, producing the BCR-ABL fusion gene. The BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives uncontrolled cell proliferation, inhibits apoptosis (programmed cell death), and promotes genomic instability, which collectively lead to the leukemic phenotype.
Dasatinib is classified as a second-generation BCR-ABL tyrosine kinase inhibitor. Unlike imatinib (the first-generation TKI), which binds only to the inactive conformation of the ABL kinase domain, dasatinib binds to both the active and inactive conformations of the enzyme. This dual-binding capability is critically important because many imatinib-resistant BCR-ABL mutations alter the kinase conformation in ways that prevent imatinib binding but still allow dasatinib to exert its inhibitory effect. In vitro studies have demonstrated that dasatinib is approximately 325-fold more potent than imatinib against wild-type (unmutated) BCR-ABL, which translates to deeper and faster molecular responses in many patients.
Beyond BCR-ABL, dasatinib inhibits a broad spectrum of other tyrosine kinases, including the entire SRC family of kinases (SRC, LCK, YES, FYN), c-KIT, EPHA2, and platelet-derived growth factor receptor beta (PDGFR-beta). The inhibition of SRC family kinases is particularly relevant because SRC kinases have been implicated in BCR-ABL-independent signaling pathways that contribute to disease progression and resistance to imatinib. This multi-targeted kinase inhibition profile gives dasatinib activity against a wider range of resistance mechanisms compared with imatinib alone.
Dasatinib Accord Healthcare is indicated for the following conditions in adult patients:
- Newly diagnosed chronic phase Ph+ CML: Dasatinib is approved as a first-line treatment for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. The pivotal DASISION trial (Dasatinib versus Imatinib Study in Treatment-Naive CML Patients) demonstrated that dasatinib 100 mg once daily achieved significantly higher rates of complete cytogenetic response (CCyR) and major molecular response (MMR) at 12 months compared with imatinib 400 mg once daily in newly diagnosed patients. Five-year follow-up data showed that dasatinib maintained superior rates of deep molecular response (MR4.5), which is increasingly recognized as a prerequisite for treatment-free remission attempts.
- Chronic phase CML with resistance or intolerance to prior therapy: Adults with chronic phase CML who are resistant to or intolerant of prior treatment, including imatinib mesylate, may benefit from dasatinib. Clinical studies have shown that dasatinib can achieve complete cytogenetic responses in a substantial proportion of patients who have failed or cannot tolerate imatinib therapy.
- Accelerated or blast phase CML: Dasatinib is approved for adults with accelerated phase or myeloid/lymphoid blast phase CML who are resistant to or intolerant of prior therapy. These advanced phases of CML carry a significantly worse prognosis, and dasatinib provides an important therapeutic option, although response rates and durability are generally lower than in chronic phase disease.
- Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Dasatinib is approved for adults with Ph+ ALL who are resistant to or intolerant of prior therapy. Ph+ ALL is an aggressive form of leukemia, and dasatinib in combination with chemotherapy has shown improved outcomes in clinical trials.
The Philadelphia chromosome is found in approximately 95% of CML cases and 20–30% of adult ALL cases. It produces the BCR-ABL fusion protein, which is the primary therapeutic target of dasatinib. Testing for the Philadelphia chromosome (by cytogenetics, FISH, or PCR for BCR-ABL transcript) is essential before starting dasatinib therapy. Molecular monitoring of BCR-ABL transcript levels is used throughout treatment to assess response and guide therapeutic decisions according to European LeukemiaNet (ELN) and NCCN guidelines.
What Should You Know Before Taking Dasatinib Accord Healthcare?
Contraindications
The primary contraindication to Dasatinib Accord Healthcare is hypersensitivity (allergy) to dasatinib or to any of the excipients in the formulation. The film-coated tablets contain excipients including lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, and magnesium stearate in the tablet core, with a film coating containing polyvinyl alcohol, titanium dioxide, macrogol, and talc. Patients with known allergies to any of these substances should not take this medication.
Additionally, dasatinib is contraindicated in patients with known long QT syndrome or uncontrolled electrolyte abnormalities (particularly hypokalemia or hypomagnesemia), as dasatinib can prolong the QTc interval and increase the risk of potentially fatal cardiac arrhythmias. Before initiating treatment, electrolyte levels should be corrected, and baseline electrocardiogram (ECG) monitoring is recommended. Dasatinib should not be initiated in patients with clinically significant, uncontrolled, or active cardiac disease.
Warnings and Precautions
Dasatinib causes severe myelosuppression (bone marrow suppression) including neutropenia, thrombocytopenia, and anemia. Complete blood counts should be performed weekly for the first 2 months and then monthly thereafter, or as clinically indicated. Severe neutropenia and thrombocytopenia may require dose interruption, dose reduction, or discontinuation of treatment. Do not start treatment if your absolute neutrophil count is below 1.5 × 109/L or platelets are below 50 × 109/L (for advanced phase disease).
Before and during treatment with dasatinib, your healthcare provider should be aware of and monitor for the following important safety concerns:
- Pleural and pericardial effusion: Fluid accumulation around the lungs (pleural effusion) is one of the most common and clinically significant side effects of dasatinib, reported in up to 35% of patients in long-term studies. Pericardial effusion (fluid around the heart) can also occur. Patients should be monitored for signs and symptoms including shortness of breath, persistent cough, chest pain, and rapid weight gain. Management may include dose interruption, dose reduction, diuretics, corticosteroids, or thoracentesis (drainage) for large effusions.
- Pulmonary arterial hypertension (PAH): Dasatinib has been associated with the development of pulmonary arterial hypertension, which can occur at any time during treatment, including after more than one year of therapy. PAH may be reversible upon discontinuation but can be serious. Patients with unexplained progressive dyspnea, fatigue, or signs of right heart failure should be evaluated for PAH with echocardiography. Dasatinib should be permanently discontinued if PAH is confirmed.
- Bleeding events: Dasatinib is associated with hemorrhagic events, including severe central nervous system (CNS) hemorrhage, gastrointestinal hemorrhage, and other serious bleeding. Patients taking anticoagulants or antiplatelet agents are at increased risk. Dasatinib also causes thrombocytopenia, which further contributes to bleeding risk. Report any unusual bleeding or bruising to your doctor immediately.
- QT prolongation: Dasatinib can prolong the QTc interval. Patients with pre-existing QT prolongation, uncontrolled or significant heart disease, or those taking medications known to prolong the QT interval should be carefully monitored. Hypokalemia and hypomagnesemia must be corrected before starting dasatinib, and electrolytes should be monitored periodically during treatment.
- Hepatotoxicity: Elevations in liver transaminases and bilirubin have been reported. Liver function tests should be performed before initiation of treatment and monitored periodically thereafter. Severe hepatotoxicity may require dose interruption, reduction, or permanent discontinuation.
- Fluid retention: In addition to pleural and pericardial effusions, dasatinib can cause other forms of fluid retention including peripheral edema, generalized edema, pulmonary edema, and ascites. Patients should be monitored for unexpected rapid weight gain and managed appropriately.
Pregnancy and Breastfeeding
Dasatinib must not be used during pregnancy. Animal studies have shown that dasatinib causes embryotoxicity and teratogenicity (birth defects). Women of childbearing potential must use highly effective contraception during treatment and for at least 30 days after the last dose. Men taking dasatinib should not father a child during treatment and for at least 30 days after the last dose. If pregnancy occurs during treatment, the patient must be informed of the potential hazard to the fetus.
Dasatinib has been shown to cause fetal harm in animal studies. In rats, dasatinib caused embryo-fetal death and skeletal abnormalities at doses significantly lower than those used in human therapy. In rabbits, dasatinib caused skeletal malformations at clinically relevant doses. There are no adequate and well-controlled studies of dasatinib in pregnant women. Based on its mechanism of action and animal data, dasatinib is expected to cause fetal harm when administered during pregnancy. If a patient becomes pregnant while taking dasatinib, she should be immediately informed of the potential risk to the fetus, and the treating physician should carefully weigh the risks and benefits of continuing therapy.
Women who are breastfeeding should not take dasatinib. It is not known whether dasatinib or its metabolites are excreted in human breast milk. However, given its molecular weight and pharmacological activity, excretion into breast milk is considered likely. Because of the potential for serious adverse reactions in breastfed infants, breastfeeding should be discontinued during treatment with dasatinib and for at least 2 weeks after the last dose.
Driving and Operating Machinery
Dasatinib may cause side effects such as dizziness, blurred vision, and fatigue that could impair the ability to drive or operate machinery. Patients who experience these symptoms should avoid driving or using machinery until the effects have resolved. No formal studies on the effects of dasatinib on the ability to drive and use machines have been performed.
How Does Dasatinib Accord Healthcare Interact with Other Drugs?
Dasatinib has a complex drug interaction profile that requires careful attention from both physicians and patients. Unlike monoclonal antibodies that have minimal drug interactions, dasatinib is a small molecule that is extensively metabolized by cytochrome P450 3A4 (CYP3A4) in the liver and is also a substrate of P-glycoprotein (P-gp). Additionally, dasatinib itself is a time-dependent inhibitor of CYP3A4, meaning it can affect the metabolism of other drugs that are CYP3A4 substrates. Understanding these interactions is essential for safe and effective therapy.
The solubility of dasatinib is pH-dependent, with optimal absorption occurring at low (acidic) pH values. This characteristic means that any medication or condition that raises gastric pH can significantly reduce dasatinib absorption and plasma levels, potentially compromising therapeutic efficacy. This is one of the most clinically important drug interaction considerations with dasatinib.
Major Interactions
| Drug / Category | Effect on Dasatinib | Clinical Recommendation |
|---|---|---|
| Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir, nefazodone) | Significantly increase dasatinib plasma levels (up to 4–5 fold) | Avoid concomitant use. If unavoidable, reduce dasatinib dose and monitor closely for toxicity. |
| Strong CYP3A4 Inducers (rifampicin, phenytoin, carbamazepine, phenobarbital, St. John's Wort) | Significantly decrease dasatinib plasma levels (up to 82% reduction with rifampicin) | Avoid concomitant use. If a CYP3A4 inducer is required, consider an alternative agent or increase dasatinib dose with close monitoring. |
| Proton Pump Inhibitors (omeprazole, esomeprazole, lansoprazole, pantoprazole) | Reduce dasatinib absorption by increasing gastric pH (up to 61% reduction in AUC) | Avoid concomitant use. Long-term suppression of gastric acid may significantly reduce dasatinib exposure. |
| H2 Receptor Antagonists (ranitidine, famotidine) | Reduce dasatinib absorption by increasing gastric pH | If needed, administer the H2 antagonist at least 10 hours before or 2 hours after dasatinib. |
| Antacids (aluminum/magnesium hydroxide, calcium carbonate) | Reduce dasatinib absorption by increasing gastric pH | Administer antacids at least 2 hours before or 2 hours after dasatinib. |
| QT-Prolonging Agents (amiodarone, sotalol, haloperidol, methadone) | Additive risk of QT prolongation and cardiac arrhythmias | Use with extreme caution. Monitor ECG and electrolytes regularly. Correct hypokalemia and hypomagnesemia. |
| Anticoagulants / Antiplatelets (warfarin, heparin, clopidogrel, aspirin) | Increased risk of hemorrhage (dasatinib inhibits platelet aggregation) | Use with caution. Monitor closely for signs of bleeding. Dasatinib inhibits platelet function in vitro. |
Additional Pharmacokinetic Considerations
Dasatinib is a time-dependent inhibitor of CYP3A4, which means it can increase the plasma concentrations of other drugs that are metabolized by this enzyme. When dasatinib is administered concomitantly with CYP3A4 substrates that have a narrow therapeutic index (such as alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, or tacrolimus), patients should be closely monitored for increased toxicity from these agents, and dose adjustments may be necessary.
Grapefruit and grapefruit juice contain compounds that inhibit CYP3A4 and should be avoided during dasatinib treatment, as they may increase dasatinib plasma levels and the risk of adverse effects. Similarly, Seville oranges and starfruit contain similar inhibitory compounds and should also be avoided.
Moderate CYP3A4 inhibitors (such as fluconazole, erythromycin, aprepitant, verapamil, and diltiazem) may also increase dasatinib levels to a lesser extent than strong inhibitors. If concomitant use is unavoidable, patients should be monitored for dasatinib toxicity, and dose reduction should be considered if adverse effects develop.
The interaction between dasatinib and acid-reducing agents is one of the most clinically significant and commonly encountered. Proton pump inhibitors (PPIs) should be avoided if possible. If acid suppression is absolutely necessary, consider using an antacid (administered 2 hours before or 2 hours after dasatinib) rather than a PPI or H2 blocker. Discuss alternative strategies for gastric acid management with your physician.
What Is the Correct Dosage of Dasatinib Accord Healthcare?
Treatment with Dasatinib Accord Healthcare should be initiated by a physician experienced in the diagnosis and treatment of patients with leukemia. The medication is available as 20 mg film-coated tablets, which can be combined to achieve the prescribed dose. Tablets should be swallowed whole at approximately the same time each day, either with or without food. They must not be crushed, cut, or chewed. If a tablet is accidentally broken or crushed, direct contact with the skin or mucous membranes should be avoided, and the area should be washed thoroughly if contact occurs.
Adults
| Indication | Recommended Dose | Frequency | Notes |
|---|---|---|---|
| Newly diagnosed chronic phase CML | 100 mg | Once daily | First-line therapy; treatment is continuous |
| Chronic phase CML (resistant/intolerant) | 100 mg | Once daily | Second-line or subsequent therapy |
| Accelerated phase CML | 140 mg | Once daily | Higher dose for advanced disease |
| Myeloid or lymphoid blast phase CML | 140 mg | Once daily | Higher dose for advanced disease |
| Ph+ ALL (resistant/intolerant) | 140 mg | Once daily | Often combined with chemotherapy |
Dose escalation may be considered in patients who do not achieve an adequate hematologic or cytogenetic response at the recommended starting dose. In chronic phase CML patients receiving 100 mg once daily, dose escalation to 140 mg once daily may be considered. In patients with advanced phase disease receiving 140 mg once daily, dose escalation to 180 mg once daily may be considered, although higher doses carry an increased risk of adverse effects, particularly pleural effusion and myelosuppression. Any dose escalation should be performed under close medical supervision.
Children and Adolescents
Dasatinib is approved for use in pediatric patients (aged 1 year and older) with newly diagnosed Ph+ CML in the chronic phase or with Ph+ CML in the chronic phase resistant or intolerant to prior therapy. The dosage in children is calculated based on body weight, using approximately 40 mg/m2 body surface area (BSA) once daily, rounded to the nearest tablet size. The actual dose should be determined by the treating hematologist/oncologist. Dasatinib tablets are not recommended for children who weigh less than 10 kg or who cannot swallow tablets whole; for these patients, a powder for oral suspension formulation (if available) may be considered.
Elderly Patients
No specific dose adjustment is recommended for elderly patients based on age alone. However, elderly patients may be more susceptible to certain adverse effects of dasatinib, including pleural effusion, fluid retention, cardiac events, and myelosuppression. Careful monitoring is advised, and dose adjustments should be made based on individual tolerance and response. Renal and hepatic function should also be considered, as age-related decline in organ function may affect drug handling.
Missed Dose
If you miss a dose of dasatinib, take it as soon as you remember on the same day. Do not take two doses at the same time to make up for a missed dose. If it is already close to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Contact your doctor or pharmacist if you are unsure about what to do.
Overdose
In the event of an overdose with dasatinib, seek emergency medical attention immediately. There is no specific antidote for dasatinib overdose. Treatment is supportive and symptomatic. Overdose has been reported in clinical trials at doses up to 280 mg per day, with primary manifestations including severe myelosuppression (very low blood counts) and bleeding. Due to the high protein binding of dasatinib (~96%), hemodialysis is unlikely to be effective in enhancing elimination.
Experience with overdose in clinical trials is limited. In cases of overdose reported during clinical development, myelosuppression and bleeding were the primary complications observed. Healthcare providers should monitor blood counts closely and provide supportive care including platelet and red blood cell transfusions as needed. Patients should be observed in a hospital setting until clinically stable.
Dose Adjustments for Adverse Reactions
Dose modifications are an essential aspect of dasatinib management. The treating physician will adjust the dose based on individual tolerability and specific adverse reactions. For hematologic adverse reactions (neutropenia, thrombocytopenia), treatment interruption and dose reduction follow specific guidelines based on disease phase and severity. For non-hematologic adverse reactions (pleural effusion, severe diarrhea, severe skin rash), the dose may be temporarily withheld until the adverse event resolves or improves, after which treatment may be resumed at the same dose or at a reduced dose. The minimum recommended doses are 80 mg once daily for chronic phase and 80 mg once daily (reduced from 140 mg) for advanced phase disease. Treatment should be permanently discontinued if an adequate response cannot be maintained at a tolerable dose.
What Are the Side Effects of Dasatinib Accord Healthcare?
Like all medicines, dasatinib can cause side effects, although not everybody gets them. The side effect profile of dasatinib is well characterized from extensive clinical trial experience involving thousands of patients, as well as from post-marketing surveillance data accumulated since its approval in 2006. The severity and incidence of adverse effects are dose-dependent and are generally more common with higher doses and in patients with advanced phase disease. Understanding the expected side effects and when to report them to your doctor is crucial for safe treatment.
The following side effect frequency grid is organized according to international medical convention: Very Common (affects more than 1 in 10 patients), Common (affects 1 in 10 to 1 in 100), Uncommon (affects 1 in 100 to 1 in 1,000), and Rare (affects fewer than 1 in 1,000 patients). Knowing the frequency helps put each side effect in perspective and guides monitoring decisions.
Very Common
Affects more than 1 in 10 patients (>10%)
- Neutropenia (low white blood cell count) – very common and can be severe
- Thrombocytopenia (low platelet count) – increases bleeding risk
- Anemia (low red blood cell count) – may cause fatigue and weakness
- Headache
- Pleural effusion (fluid around the lungs) – characteristic side effect
- Diarrhea
- Nausea
- Skin rash
- Musculoskeletal pain (bone, joint, or muscle pain)
- Fatigue
- Superficial edema (swelling, including facial and periorbital edema)
- Infections (including upper respiratory tract infections)
Common
Affects 1 in 10 to 1 in 100 patients (1–10%)
- Febrile neutropenia (fever with low white blood cells)
- Pneumonia and other serious infections
- Herpes virus infections
- Hemorrhage (gastrointestinal, CNS, or other sites)
- Pericardial effusion (fluid around the heart)
- Congestive heart failure / cardiac dysfunction
- QT prolongation on ECG
- Elevated liver enzymes (ALT, AST) and bilirubin
- Vomiting
- Abdominal pain
- Appetite loss (anorexia)
- Weight gain or loss
- Dizziness
- Peripheral neuropathy
- Blurred vision
- Dyspnea (shortness of breath)
- Cough
- Pruritus (itching)
- Alopecia (hair thinning or loss)
- Acne
- Arthralgia (joint pain)
- Myalgia (muscle pain)
- Muscle inflammation or weakness
- Pyrexia (fever)
- Chest pain
- Asthenia (weakness)
Uncommon
Affects 1 in 100 to 1 in 1,000 patients (0.1–1%)
- Pulmonary arterial hypertension (PAH)
- Myocardial infarction (heart attack)
- Hepatitis and liver failure
- Pancreatitis
- Tumor lysis syndrome
- Severe skin reactions (erythema multiforme, Stevens-Johnson syndrome)
- Renal failure
- Pulmonary edema
- Chylothorax
- Seizures
- Amnesia and confusion
- Ventricular arrhythmia (including torsades de pointes)
- Osteonecrosis
- Gynecomastia
- Irregular menstruation
Rare
Affects fewer than 1 in 1,000 patients (<0.1%)
- Pure red cell aplasia
- Thrombotic microangiopathy
- Livedo reticularis
- Nephrotic syndrome
- Fatal pulmonary arterial hypertension
Contact your healthcare provider immediately or seek emergency medical care if you experience: unexplained bruising or bleeding (including blood in stool or urine), sudden onset of shortness of breath or persistent cough, chest pain or palpitations, high fever or signs of infection, severe abdominal pain, yellowing of skin or eyes (jaundice), sudden severe headache or vision changes, or significant swelling of limbs or face. These may be signs of serious adverse effects requiring urgent medical evaluation.
Long-term follow-up data from clinical trials and registries have provided important additional safety information. With extended treatment duration, the cumulative incidence of pleural effusion increases, with rates reaching approximately 33–35% at 5 years in the first-line setting. However, most pleural effusions are manageable with dose interruption and supportive care, and the majority of affected patients are able to continue dasatinib therapy, sometimes at a reduced dose. The risk of pulmonary arterial hypertension, while uncommon, remains a concern that requires ongoing vigilance, as it can develop even after several years of uneventful treatment.
It is worth noting that many side effects of dasatinib, particularly myelosuppression, are pharmacologically predictable consequences of its mechanism of action. BCR-ABL kinase activity is present in normal hematopoietic cells, and the inhibition of SRC family kinases and other targets also affects normal cellular processes. The treating physician will balance the benefits of leukemia control against the risks of adverse effects, using dose modifications, supportive care, and monitoring to optimize the therapeutic outcome for each individual patient.
How Should You Store Dasatinib Accord Healthcare?
Proper storage of dasatinib is important to maintain the quality, efficacy, and safety of the medication throughout its shelf life. Dasatinib Accord Healthcare film-coated tablets should be stored at room temperature, not exceeding 30°C (86°F). No special temperature-controlled storage (such as refrigeration) is required, making it convenient for home storage. However, the tablets should not be exposed to excessive heat, direct sunlight, or conditions of high humidity.
The tablets should be kept in their original packaging (blister packs within the outer carton) to protect them from moisture. Moisture can degrade the active pharmaceutical ingredient and compromise the integrity of the film coating. Do not transfer the tablets to different containers unless specifically instructed by your pharmacist. If your pharmacist provides the tablets in a different container, ensure it is tightly sealed and stored in a dry place.
Always check the expiry date printed on the carton and blister pack before taking the medication. Do not use Dasatinib Accord Healthcare after the expiry date stated on the packaging. The expiry date refers to the last day of that month. If you notice any visible changes in the appearance of the tablets (such as discoloration, crumbling, or unusual odor), do not use them and consult your pharmacist.
Keep this medicine out of the sight and reach of children. As dasatinib is an anticancer medication with significant pharmacological activity, accidental ingestion by children could cause serious harm. Store the medication in a secure location. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use, as these measures will help protect the environment. Many pharmacies offer medication take-back programs for safe disposal of unused anticancer medications.
What Does Dasatinib Accord Healthcare Contain?
Dasatinib Accord Healthcare 20 mg film-coated tablets contain dasatinib as the active substance. Each tablet contains exactly 20 mg of dasatinib. The active substance is responsible for the pharmacological effects of the medicine, specifically the inhibition of BCR-ABL and related tyrosine kinases that are the therapeutic targets in CML and Ph+ ALL.
The tablet core also contains the following excipients (inactive ingredients), which are necessary for the manufacturing process, tablet integrity, stability, and dissolution characteristics:
- Lactose monohydrate: A filler/diluent that helps create the tablet bulk. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
- Microcrystalline cellulose: A commonly used pharmaceutical excipient that serves as a binder and filler, contributing to the mechanical strength of the tablet.
- Croscarmellose sodium: A disintegrant that helps the tablet break apart in the gastrointestinal tract, facilitating release and absorption of the active substance.
- Hydroxypropyl cellulose: A binder that helps hold the tablet components together during the compression process.
- Magnesium stearate: A lubricant used in the tablet manufacturing process to prevent the tablet mixture from sticking to equipment during compression.
The film coating of the tablet contains:
- Polyvinyl alcohol: The primary film-forming polymer that creates the coating layer.
- Titanium dioxide (E171): A white colorant that gives the tablet its white or off-white appearance and provides protection from light.
- Macrogol (polyethylene glycol): A plasticizer that makes the film coating flexible and uniform.
- Talc: An anti-tacking agent that prevents the coated tablets from sticking together during the coating process.
The 20 mg tablets are white to off-white, biconvex, round film-coated tablets. The tablets may have debossing or markings for identification purposes. If you are uncertain about the identity of your tablets, consult your pharmacist. It is important to note that the tablet formulation is designed for oral administration only; the tablets should be swallowed whole and must not be dissolved in liquid, crushed, or prepared extemporaneously for alternative routes of administration.
Frequently Asked Questions About Dasatinib Accord Healthcare
Dasatinib Accord Healthcare is a generic formulation of dasatinib, while SPRYCEL is the original brand-name product developed by Bristol-Myers Squibb. Both contain the same active substance (dasatinib) and have been shown to be bioequivalent, meaning they deliver the same amount of the active drug to the body at the same rate. Generic medicines must meet the same rigorous quality, safety, and efficacy standards as the originator product. The main difference is typically the price, as generic medicines are generally more affordable than brand-name products. Your doctor or pharmacist can advise you on whether switching between formulations is appropriate in your situation.
Yes, dasatinib can be taken with or without food. Food does not significantly affect the overall absorption of dasatinib, although a high-fat meal may increase the exposure (AUC) by approximately 14%, which is not considered clinically significant. The most important dietary consideration is to avoid grapefruit and grapefruit juice, as these contain CYP3A4 inhibitors that can increase dasatinib levels. Seville oranges and starfruit should also be avoided for the same reason. Take the tablets with a glass of water at approximately the same time each day for consistency.
The duration of dasatinib treatment varies depending on the disease, the response to treatment, and individual patient circumstances. For chronic phase CML, treatment is typically long-term and may continue indefinitely as long as the patient continues to benefit and tolerates the medication. However, for patients who achieve a sustained deep molecular response (typically defined as MR4 or MR4.5 maintained for at least 2 years), treatment-free remission (TFR) may be attempted under close molecular monitoring. This means that in select patients, dasatinib may be discontinued, with approximately 50% of eligible patients maintaining their response without treatment. Your hematologist will guide you through this decision based on current ELN and NCCN guidelines. Never stop taking dasatinib without consulting your doctor.
Shortness of breath (dyspnea) during dasatinib treatment should be taken seriously, as it may be a sign of pleural effusion (fluid buildup around the lungs) or, less commonly, pulmonary arterial hypertension. Contact your doctor promptly if you develop new or worsening shortness of breath, persistent cough, chest pain, or difficulty breathing when lying flat. Your doctor will likely perform a chest X-ray or CT scan to check for pleural effusion. Management may include temporary interruption of dasatinib, diuretics, and in some cases, thoracentesis (drainage of fluid). Most patients with pleural effusion are able to resume dasatinib treatment, often at a reduced dose. If pulmonary arterial hypertension is suspected, an echocardiogram will be performed, and dasatinib may need to be permanently discontinued.
Yes, dasatinib is specifically designed and approved for the treatment of CML patients who are resistant to or intolerant of imatinib. Dasatinib is active against most imatinib-resistant BCR-ABL mutations because it binds to both the active and inactive conformations of the ABL kinase and is 325 times more potent than imatinib against unmutated BCR-ABL. In clinical studies, dasatinib achieved complete cytogenetic responses in approximately 40–55% of chronic phase CML patients who had failed imatinib therapy. However, dasatinib is not effective against the T315I gatekeeper mutation; patients with this specific mutation may require ponatinib or other treatment strategies. BCR-ABL mutation analysis is an important tool for selecting the most appropriate TKI after imatinib failure.
While there is no specific contraindication to moderate alcohol consumption during dasatinib treatment, it is generally advisable to limit or avoid alcohol. Alcohol can contribute to liver toxicity (dasatinib also affects the liver), may worsen gastrointestinal side effects such as nausea and diarrhea, and can compound the dizziness and fatigue that some patients experience. Additionally, excessive alcohol consumption can affect the immune system, which is already compromised by dasatinib-related myelosuppression. Discuss your alcohol consumption habits with your treating physician for personalized advice.
References
- European Medicines Agency (EMA). Dasatinib – Summary of Product Characteristics. Last updated 2025. Available from: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). SPRYCEL (dasatinib) Prescribing Information. Revised 2024. Available from: www.accessdata.fda.gov
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 1.2025. Available from: www.nccn.org
- Hochhaus A, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
- Kantarjian HM, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia (DASISION): 5-year follow-up. New England Journal of Medicine. 2012;367(21):2000–2009. doi:10.1056/NEJMoa1113201
- Cortes JE, et al. Long-term follow-up of dasatinib 100 mg once daily in newly diagnosed chronic myeloid leukemia: DASISION 5-year update. Leukemia. 2021;35(7):1996–2008.
- Shah NP, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399–401. doi:10.1126/science.1099480
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Chronic Myeloid Leukemia. Last updated 2024. Available from: www.esmo.org
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List (2023). Dasatinib included for CML treatment.
- British National Formulary (BNF). Dasatinib monograph. Last updated 2025. Available from: bnf.nice.org.uk
Medical Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Oncology, Hematology, and Clinical Pharmacology
Medical Review
iMedic Medical Review Board – Independent expert panel following GRADE evidence framework
Quality Assurance
Content reviewed according to EMA SmPC, FDA labeling, NCCN and ESMO clinical guidelines
Last Review
January 12, 2026 – Evidence Level 1A based on systematic reviews and randomized controlled trials
All medical content on iMedic is independently created by licensed healthcare professionals. We follow international editorial standards and have no commercial funding or pharmaceutical company sponsorship. Learn more about our medical team.